Through our core commitments, we are leveraging our scale for the greater good, such as serving the needs of our stakeholders, donating back to our communities, protecting our planet, working with policymakers, and more.
We distribute pharmaceuticals and medical supplies to healthcare settings across North America, from pharmacies and hospitals to doctors’ offices and clinics.
We provide a suite of solutions designed to address access, affordability and adherence challenges by bridging the gaps between biopharma companies, pharmacies, providers, and payers to help patients get on and stay on their medications.
We offer solutions that enable employers, payers, health-plan brokers and government agencies to provide lower-cost options for prescription medications and therapies.
When it comes to rare blood disorders, navigating the path to care is often anything but straightforward. Patients may face an array of challenges, including delayed diagnosis, limited access to specialists and access to medications they need for care.
Innovative Hematology (IHI) is home to Indiana’s only federally designated hemophilia treatment center, the Indiana Hemophilia & Thrombosis Center (IHTC). IHTC has long been a lifeline for patients with conditions like hemophilia A and B, von Willebrand disease and sickle cell disease. But even with a team of more than 40 providers, they knew they weren’t reaching everyone who needed them. The question was: Where were the gaps?
That’s where ²ÝÝ®ÊÓÆµ CompileTM came in.
“We believe that data should do more than describe the past, it should illuminate the path forward,” said Veena Attivilli, vice president of Customer Success and Real-World Data Analytics at ²ÝÝ®ÊÓÆµ Compile. “Our goal with IHI was to help them see the full picture of their potential patient landscape and support their mission of providing expert care to the greatest number of Indiana patients.”
Using a combination of Patient ReadyData™ and Provider 360 ReadyData, we built a custom analysis that mapped out the rare blood disorder landscape across Indiana and beyond. With these insights, IHI could now see which providers were treating and referring patients with rare blood disorders, the organizations they were affiliated with and a breakdown of patient volumes for each.
The data revealed potentially underserved regions, non-specialized providers who could benefit from targeted education and referral patterns that extended across state lines. Armed with this intelligence, IHI launched a series of strategic initiatives including strengthening provider networks, refining referral processes and expanding outreach to help ensure more patients can access the care they need.
This wasn’t just about numbers on a dashboard. It was about empowering IHI to close care gaps with real-world data.
Veena Attivilli
Vice President of Customer Success and Real-World Data Analytics
The impact has been noticeable. IHI is now better equipped to identify treatment-ready patients, engage with providers who need support and ultimately deliver on the organization’s mission of providing the best comprehensive, coordinated care for rare blood disorders.
For us, the partnership is a powerful example of how connected data and analytics can drive health equity and improve outcomes especially for those with the most complex needs.
“Closing care gaps starts with seeing them clearly,” added Attivilli. “And that’s exactly what we help our partners do.”
Related Stories
How Biopharma and community oncology are working together to solve healthcare’s toughest challenges and build a more resilient future for cancer care.
How Biopharma and community oncology are working together to solve healthcare’s toughest challenges and build a more resilient future for cancer care.
In the third episode of our Always Advancing video series, learn how precision and personalized medicine are transforming cancer care – expanding access to clinical trials and novel treatments in communities.
In the third episode of our Always Advancing video series, learn how precision and personalized medicine are transforming cancer care – expanding access to clinical trials and novel treatments in communities.
InspiroGene by ²ÝÝ®ÊÓÆµ helps patients with rare and severe diseases access innovative cell and gene therapies through personalized support at every step of their journey.
InspiroGene by ²ÝÝ®ÊÓÆµ helps patients with rare and severe diseases access innovative cell and gene therapies through personalized support at every step of their journey.
In the fourth episode of our Always Advancing video series, discover how InspiroGene by ²ÝÝ®ÊÓÆµ partners with biopharma to expand patient access to advanced therapies.
In the fourth episode of our Always Advancing video series, discover how InspiroGene by ²ÝÝ®ÊÓÆµ partners with biopharma to expand patient access to advanced therapies.
In the second episode of our Always Advancing series, we explore how ²ÝÝ®ÊÓÆµ and biopharma are breaking barriers to accelerate access to lifesaving therapies.
In the second episode of our Always Advancing series, we explore how ²ÝÝ®ÊÓÆµ and biopharma are breaking barriers to accelerate access to lifesaving therapies.